Semantic Scholar uses AI to extract papers important to this topic.
Long-term use of levodopa (L-dopa) in patients with Parkinson's disease is associated with development of dyskinesia. This study… Expand Apart from Huntington's disease, little is known of the genetics of autosomal dominant chorea associated with dystonia. Here we… Expand This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist… Expand The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial… Expand BACKGROUND
Modulation of metabotropic glutamate receptors may be a novel therapeutic approach to manage L-Dopa-induced… Expand AFQ056 is a novel, selective metabotropic glutamate receptor 5 antagonist. This was a 13‐week, double‐blind, placebo‐controlled… Expand An antagonist for the metabotropic glutamate receptor may improve symptoms in patients with fragile X syndrome whose FMR1… Expand Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa… Expand Fragile X syndrome, the most common form of inherited intellectual disability, is caused by a lack of FMRP, which is the product… Expand Overactivity of glutamatergic transmission has been implicated in Parkinson's disease (PD) and levodopa (L-Dopa)-induced… Expand